Potent inhibition of necroptosis by simultaneously targeting multiple effectors of the pathway
Details
Publication Year 2020-09-22, Volume 15, Issue #19, Page 2702-2713
Journal Title
ACS Chemical Biology
Publication Type
Journal epub ahead of print
Abstract
Necroptosis is an inflammatory form of programmed cell death that has been implicated in various human diseases. Compound 2 is a more potent analogue of the published compound 1 and inhibits necroptosis in human and murine cells at nanomolar concentrations. Several target engagement strategies were employed, including cellular thermal shift assays (CETSA) and diazirine-mediated photoaffinity labeling via a bifunctional photoaffinity probe derived from compound 2. These target engagement studies demonstrate that compound 2 binds to all three necroptotic effector proteins (mixed lineage kinase domain-like protein (MLKL), receptor-interacting serine/threonine protein kinase 1 (RIPK1) and receptor-interacting serine/threonine protein kinase 3 (RIPK3)) at different levels in vitro and in cells. Compound 2 also shows efficacy in vivo in a murine model of systemic inflammatory response syndrome (SIRS).
Publisher
ACS
WEHI Research Division(s)
Structural Biology; Blood Cells And Blood Cancer; Inflammation; Chemical Biology
PubMed ID
32902249
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2020-10-17 02:40:37
Last Modified: 2020-11-03 10:20:37
An error has occurred. This application may no longer respond until reloaded. Reload 🗙